In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US healthcare giant Johnson & Johnson subsidiary has released positive top-line results from the three-arm Phase III MARIPOSA-2 study evaluating Rybrevant (amivantamab-vmjw) in lung cancer patients. 6 September 2023
Pharmaceutical
The UK is an attractive place to conduct life science research and development (R&D). However, we must caveat this statement with the words, ‘for now’. 6 September 2023
Pharmaceutical
Cambridge, US-based Apollo Therapeutics today announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital. 6 September 2023
Biotechnology
Jane Grogan has been named as executive vice president, head of research at US biotech major Biogen, with the appointment taking effective on October 2. 6 September 2023
Pharmaceutical
US pharma company Tonix Pharmaceuticals Holding Corp lost nearly 9% of its stock market value on Tuesday. 6 September 2023
Biotechnology
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz). 6 September 2023
Pharmaceutical
Marie-France Tschudin, president, innovative medicines international and chief commercial officer of Novartis, has decided to leave the Swiss pharma giant and will step down from the executive committee of Novartis. 6 September 2023
Pharmaceutical
Dr Monica Shaw has joined the commercial leadership team of US pharma major Bristol Myers Squibb’s as senior vice president, major markets. 6 September 2023
Pharmaceutical
Egypt is set to join BRICS next year as the bloc expands to include six new members. 6 September 2023
Biotechnology
Idorsia is to pay up to $345 million to reacquire rights to aprocitentan, a novel endothelin receptor blocker under development for hypertension. 6 September 2023
Biotechnology
Adding to an earlier setback, cellular and cell-derived drug developer BioCardia (Nasdaq: BCDA), yesterday announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP Cell Therapy for Heart Failure (CardiAMP HF) which disappointed. 6 September 2023
Pharmaceutical
The Russian segment of drug public procurements significantly declined this year, mainly as a result of a significant drop of purchases under various state programs, The Pharma Letter’s local correspondent reports. 6 September 2023
Generics
Russian drugmaker Geropharm once again failed to challenge the patent for Toujeo (long-acting insulin glargine) produced by the French pharma major Sanofi, reports The Pharma Letter’s local correspondent. 5 September 2023
Biotechnology
US biotech Star Therapeutics has announced the closing of an oversubscribed $90 million Series C financing to continue growing its antibody therapies and portfolio companies. 5 September 2023
Biotechnology
US biotech major Amgen’s olpasiran, a small interfering RNA (siRNA), is making strides in reducing lipoprotein [Lp(a)] levels significantly in patients with cardiovascular disease. 5 September 2023
Biotechnology
Partners Sage Therapeutics and Biogen secured US approval for Zurzuvae (zuranolone) for adults with postpartum depression (PPD) last month. 5 September 2023
Pharmaceutical
Shares of Spanish dermatology-focused drugmaker Almirall rallied yesterday, after the company revealed in a brief stock exchange filing that it is looking to expand its therapeutic range. 5 September 2023
Biotechnology
New Phase III innovaTV 301 global trial data in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). 5 September 2023
Pharmaceutical
Italy’s privately-held drug developer Italfarmaco Group today revealed that its Marketing Authorization Application (MAA) for Givinostat as a potential treatment for Duchenne muscular dystrophy (DMD) has been submitted to the European Medicine Agency. 5 September 2023
Pharmaceutical
Palforzia was going to be the keystone product in Nestle’s strategic expansion into biotech, but the Swiss food and drink giant has finally thrown in the towel. 5 September 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze